A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell
A phase 3 trial of Atezolizumab, Bevacizumab, Tiragolumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) is a phase 3 interventional study registered as NCT05904886 by Hoffmann-La Roche, with 687 participants enrolled, started 2023-09-14 and due to reach its primary completion in 2025-05-08. Interventions recorded: Atezolizumab, Bevacizumab, Tiragolumab, Placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li
Shares Tiragolumab, Atezolizumab, Roche / Genentech, Bevacizumab.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Shares Tiragolumab, Atezolizumab, Roche / Genentech.
- TrialA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Shares Tiragolumab, Atezolizumab.
- TrialStudy of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialPhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.